TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10029562

Group type: EXPERIMENTAL
Intervention: Angiotensin II (1.0 ng x min‐1 x kg‐1 and 3.0 ng x min‐1 x kg‐1 for 30 min)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Angiotensin II (1.0 ng x min‐1 x kg‐1 and 3.0 ng x min‐1 x kg‐1 for 120 min)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Angiotensin II (3.0 ng x min‐1 x kg‐1 for 30 min followed by dose increment every 30 min until mean blood pressure increased by 25 mmHg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Angiotensin II (1.0 ng x min‐1 x kg‐1 followed by 3.0 ng x min‐1 x kg‐1 for 60 min on two different NaCl diets)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Angiotensin II (10(‐9), 10(‐8), 10(‐7) mol/l) in cultured human vascular endothelial cells
Number of subjects: 31

Group type: COMPARATOR
Intervention: Candesartan cilexetil (AT1 receptor inhibitor)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Actinomycin D (RNA synthesis inhibitor)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Cycloheximide (protein synthesis inhibitor)
Number of subjects: 31
Study: 7477812

Group type: EXPERIMENTAL
Intervention: Glucose drink
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low baseline blood glucose levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High baseline blood glucose levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose drink with fail in blood glucose
Number of subjects: 0
Study: 2180889

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and benzylpenicillin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Netilmicin and piperacillin
Number of subjects: 97
Study: 453298

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (550 mg initially, followed by 275 mg every 6 hours as needed)
Number of subjects: 33
Study: 31307843

Group type: EXPERIMENTAL
Intervention: EAA supplementation (15 g daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (supervised progressive vigorous treadmill walking 3 times weekly)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ex with EAA supplementation (Ex + EAA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ex with placebo (Ex + PLA)
Number of subjects: 42
Study: 29538089

Group type: EXPERIMENTAL
Intervention: Treatment Responders (TRs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment Nonresponders (TNRs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication-assisted treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early treatment response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal estimated gestational age (EGA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline cocaine use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early treatment nonresponse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline SUD treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline marijuana use
Number of subjects: 0
Study: 27634054

Group type: EXPERIMENTAL
Intervention: Hysteroscopy monitoring
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ultrasonography monitoring
Number of subjects: 144

Group type: COMPARATOR
Intervention: No monitoring
Number of subjects: 144
Study: 24614377

Group type: EXPERIMENTAL
Intervention: Standard dose (400/100 mg BID)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Increased dose (600/150 mg BID)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standard dose (400/100 mg BID) after childbirth
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Increased dose (600/150 mg BID) after childbirth
Number of subjects: 60
Study: 22821790

Group type: EXPERIMENTAL
Intervention: Protocol-based pharmacist intervention (patient education, home blood pressure monitoring, referral to physician)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Protocol-based pharmacist intervention
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 176
Study: 20087081

Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg daily)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 18077778

Group type: EXPERIMENTAL
Intervention: Elk velvet antler
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 15895892

Group type: EXPERIMENTAL
Intervention: High molecular weight HA (Hylan G‐F 20) injections
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Low molecular weight HA (Orthovisc) injections
Number of subjects: 92

Group type: COMPARATOR
Intervention: Both HA preparations (High molecular weight and Low molecular weight)
Number of subjects: 92
Study: 14511969

Group type: EXPERIMENTAL
Intervention: Educational counselling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 0
Study: 10502228

Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame count (cTFC)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Final TIMI flow
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Final TIMI flow (in patients with analyzable cTFC)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: TIMI flow grade
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Infarct location
Number of subjects: 390
Study: 8983276

Group type: EXPERIMENTAL
Intervention: Large core biopsy
Number of subjects: 41
Study: 1669388

Group type: EXPERIMENTAL
Intervention: Laser
Number of subjects: 300

Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study: 7340376

Group type: EXPERIMENTAL
Intervention: Fentanyl 50 μg.kg‐1
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fentanyl 10 μg.kg‐1
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fentanyl 30 μg.kg‐1
Number of subjects: 25
Study: 6429481

Group type: EXPERIMENTAL
Intervention: Combination of 17 beta-oestradiol 2 mg plus oestriol 1 mg for 12 days, followed by 17 beta-oestradiol 2 mg plus norethisterone acetate 1 mg for 10 days, and then 17 beta-oestradiol 1 mg plus oestriol 0.5 mg for 6 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Combination of 17 beta-oestradiol 2 mg plus norethisterone acetate 1 mg for 12 days, followed by 17 beta-oestradiol 2 mg plus norethisterone acetate 1 mg for 10 days, and then 17 beta-oestradiol 1 mg for 6 days (without oestriol)
Number of subjects: 43
Study: 30621368

Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Cervical mobilization
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 83
Study: 29284788

Group type: EXPERIMENTAL
Intervention: Dose 1 Curry
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dose 2 Curry
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dose 0 Control
Number of subjects: 20
Study: 26517858

Group type: EXPERIMENTAL
Intervention: Duloxetine (titrated up to 120 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 41
Study: 24255991

Group type: EXPERIMENTAL
Intervention: Bathing in geothermal seawater combined with NB‐UVB therapy three times a week
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intensive daily treatment involving bathing in geothermal seawater combined with NB‐UVB therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: NB‐UVB therapy alone three times a week
Number of subjects: 68
Study: 22153280

Group type: EXPERIMENTAL
Intervention: Spinal analgesia
Number of subjects: 97

Group type: COMPARATOR
Intervention: Repeat epidural
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Spinal analgesia and Repeat epidural
Number of subjects: 97
Study: 19915480

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg + Haloperidol 1.5 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Dexamethasone 8 mg + Placebo
Number of subjects: 160
Study: 17975386

Group type: EXPERIMENTAL
Intervention: Early renal replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard timing of renal replacement therapy
Number of subjects: 0
Study: 16249547

Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg/day for 12 months (group B1)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (group B2)
Number of subjects: 58
Study: 11844826

Group type: EXPERIMENTAL
Intervention: Vorozole (2.5 mg per day for 12 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg per day for 12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 100
Study: 10091968

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (one-hour session)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Written information about the risks related to drinking during pregnancy
Number of subjects: 42
Study: 7789450

Group type: COMPARATOR
Intervention: Unopposed flexions of about 55‐70 degrees (control trials)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Movements opposed by spring‐like loads generated by a torque motor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Movements opposed by high loads (80‐90% of maximal voluntary contraction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High load conditions
Number of subjects: 0
Study: 2104074

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (500 mg t.d.s.)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 373646

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate delivered as an aerosol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate delivered as a powder from a rotahaler
Number of subjects: 14
Study: 30295512

Group type: EXPERIMENTAL
Intervention: Residual pseudo-likelihood estimator using GLIMMIX procedure of SAS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Method of moments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Analysis of variance estimators
Number of subjects: 0
Study: 29061068

Group type: EXPERIMENTAL
Intervention: Three-layer PR technique using peritoneum
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard PR technique
Number of subjects: 48
Study: 26209422

Group type: EXPERIMENTAL
Intervention: Advanced reciprocating gait orthosis with thoracolumbosacral orthosis
Number of subjects: 4

Group type: COMPARATOR
Intervention: Advanced reciprocating gait orthosis without thoracolumbosacral orthosis
Number of subjects: 4
Study: 24398053

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg once daily at bedtime
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 22672145

Group type: EXPERIMENTAL
Intervention: 0.03% DSC127
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 0.01% DSC127
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 19463030

Group type: EXPERIMENTAL
Intervention: Psychoeducational music therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Psychoeducational control
Number of subjects: 105
Study: 17126472

Group type: EXPERIMENTAL
Intervention: Esophageal tracheal combitube (ETC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tracheal intubation (TI)
Number of subjects: 20
Study: 15023156

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Everolimus 3 mg/day
Number of subjects: 493

Group type: COMPARATOR
Intervention: Everolimus (both doses)
Number of subjects: 493
Study: 11117910

Group type: COMPARATOR
Intervention: Diltiazem (rate control)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Amiodarone (rhythm control)
Number of subjects: 252
Study: 9179323

Group type: EXPERIMENTAL
Intervention: Likert-type format
Number of subjects: 0

Group type: COMPARATOR
Intervention: Garfield format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Above average students with Garfield format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average students with Garfield format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average students with Likert-type format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Below average students with Likert-type format
Number of subjects: 0
Study: 8212823

Group type: EXPERIMENTAL
Intervention: Booster dose given to 34 children with anti-HBs titres lower or slightly higher than 100 IU l‐1
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Initial vaccination against hepatitis B
Number of subjects: 79
Study: 3082179

Group type: EXPERIMENTAL
Intervention: Neutron-beam irradiation (25-30 Gy boost)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Photon-beam irradiation (25-30 Gy boost)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Neutron-beam irradiation
Number of subjects: 115

Group type: COMPARATOR
Intervention: Photon-beam irradiation
Number of subjects: 115
Study: 31861951

Group type: EXPERIMENTAL
Intervention: Magnesium alginate
Number of subjects: 72

Group type: COMPARATOR
Intervention: Thickened formula
Number of subjects: 72
Study: 28275307

Group type: EXPERIMENTAL
Intervention: Hydrotalcite combined with esomeprazole
Number of subjects: 48

Group type: COMPARATOR
Intervention: Esomeprazole alone
Number of subjects: 48
Study: 26674505

Group type: EXPERIMENTAL
Intervention: Nitinol closure clip
Number of subjects: 46

Group type: COMPARATOR
Intervention: RMAF procedure
Number of subjects: 46
Study: 23364004

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (10 μg vitamin D(3)/d and 1.2 g Ca/d, with 375 μg weekly)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (equivalent to 63 μg (2500 IU)/d and 10 μg (400 IU)/d)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Weight loss (WL)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Weight maintenance (WM)
Number of subjects: 82
Study: 21487114

Group type: EXPERIMENTAL
Intervention: Self-uncertainty manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thinking about a self-expressive possession
Number of subjects: 0
Study: 17584993

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 0
Study: 16734552

Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.4 IU/kg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Insulin ultralente
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.3 IU/kg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Insulin glargine (tailor-made dose)
Number of subjects: 71
Study: 12617377

Group type: EXPERIMENTAL
Intervention: Multisensory stimulation (MSE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Relaxation activities (control group)
Number of subjects: 12
Study: 10833675

Group type: EXPERIMENTAL
Intervention: Relaxation training (10-week, group-based cognitive-behavioral stress management intervention)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 30
Study: 9165640

Group type: EXPERIMENTAL
Intervention: Pay ($3.40/hr)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No-Pay
Number of subjects: 150
Study: 7903572

Group type: EXPERIMENTAL
Intervention: Arnica Montana
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo or no treatment)
Number of subjects: 0
Study: 2423408

Group type: EXPERIMENTAL
Intervention: Amylase inhibitor
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31050930

Group type: EXPERIMENTAL
Intervention: Photon Lase III (100 mW, 4 J/cm2‐1 J/cm2 each point, 10 sec per point with wavelength of 808 nm)
Number of subjects: 60
Study: 30487757

Group type: EXPERIMENTAL
Intervention: Abdominal binding (AB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 20
Study: 28255259

Group type: EXPERIMENTAL
Intervention: Psoas compartment block and sciatic nerve block (PCS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unilateral spinal anaesthesia (USA)
Number of subjects: 60
Study: 24333515

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging/transrectal ultrasound fusion guided biopsy
Number of subjects: 105
Study: 24367568

Group type: EXPERIMENTAL
Intervention: Simple group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Complex group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Random group
Number of subjects: 36
Study: 20545217

Group type: EXPERIMENTAL
Intervention: 0.0015% tafluprost ophthalmic solution
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo ophthalmic solution
Number of subjects: 94
Study: 19085497

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis during total hip arthroplasty (exact intervention details not provided)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis during total hip arthroplasty
Number of subjects: 188
Study: 16619567

Group type: EXPERIMENTAL
Intervention: PS76A2 (15 ng mistletoe lectin/0.5 ml)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: PS76A2
Number of subjects: 352
Study: 12746765

Group type: EXPERIMENTAL
Intervention: Fluconazole plus placebo (800 mg per day)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Fluconazole plus amphotericin B (0.7 mg/kg per day for the first 5-6 days)
Number of subjects: 219
Study: 10810947

Group type: EXPERIMENTAL
Intervention: Printed educational materials designed to encourage patients to quit smoking, eat less fat, and increase physical activity.
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Physician advice to quit smoking, eat less fat, or get more exercise prior to receiving intervention materials.
Number of subjects: 915
Study: 7531023

Group type: EXPERIMENTAL
Intervention: Electrochemical therapy (ECT) with systemic chemotherapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Electrochemical therapy (ECT) alone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (systemic chemotherapy alone)
Number of subjects: 26
Study: 3279010

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg orally four times a day for 2 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: COMPARATOR
Intervention: Running-in period
Number of subjects: 11
Study: 30048331

Group type: EXPERIMENTAL
Intervention: Lung Ultrasound score at positive end‐expiratory pressure 5
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lung Ultrasound score at positive end‐expiratory pressure 15
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Regional Lung Ultrasound score at positive end‐expiratory pressure 5
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Regional Lung Ultrasound score at positive end‐expiratory pressure 15
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Each step increase of regional Lung Ultrasound score
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Regional Lung Ultrasound score and CT classification at positive end‐expiratory pressure 5
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Regional Lung Ultrasound score and CT classification at positive end‐expiratory pressure 15
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Global Lung Ultrasound score at positive end‐expiratory pressure 15
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Not aerated tissue at positive end‐expiratory pressure 15
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lung Ultrasound score variations
Number of subjects: 20
Study: 28388937

Group type: EXPERIMENTAL
Intervention: Experience-based co-design intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 27707450

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual Activity
Number of subjects: 186
Study: 23649964

Group type: EXPERIMENTAL
Intervention: Brivaracetam 100 mg single oral dose in participants with mild hepatic impairment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Brivaracetam 100 mg single oral dose in participants with moderate hepatic impairment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Brivaracetam 100 mg single oral dose in participants with severe hepatic impairment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Brivaracetam 100 mg single oral dose in healthy controls
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of brivaracetam disposition in hepatic impairment versus healthy controls
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Brivaracetam metabolism in hepatic impairment
Number of subjects: 26
Study: 22191234

Group type: EXPERIMENTAL
Intervention: Phototherapeutic treatment in addition to standard radio- and hormonal therapy (n=308)
Number of subjects: 559

Group type: COMPARATOR
Intervention: Standard radio- and hormonal therapy alone (n=251)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Overall survival in the study group (localized and generalized tumors)
Number of subjects: 559
Study: 19088057

Group type: EXPERIMENTAL
Intervention: Eccentric loading
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Eccentric loading plus shock-wave treatment
Number of subjects: 68
Study: 17452150

Group type: EXPERIMENTAL
Intervention: 30 mg/d of pioglitazone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no pioglitazone)
Number of subjects: 28
Study: 15284252

Group type: EXPERIMENTAL
Intervention: Irinotecan treatment continued until disease progression (n = 25)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Irinotecan treatment stopped after 8 cycles (n = 30)
Number of subjects: 333
Study: 11506437

Group type: EXPERIMENTAL
Intervention: 30-day continuous wear
Number of subjects: 504

Group type: COMPARATOR
Intervention: 7-day extended wear
Number of subjects: 504
Study: 9754822

Group type: EXPERIMENTAL
Intervention: Linomide 2.5 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 7872447

Group type: EXPERIMENTAL
Intervention: Nopikex soap (20% diethyl toluamide and 0.5% permethrin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo soap
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 2191485

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy (rt-PA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous thrombolytic therapy (streptokinase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early intervention with PTCA or surgery
Number of subjects: 0